Chris Raymond Analyst Performance

Chris Raymond has covered the biopharma sector for over 25 years, covering a broad spectrum of large-, mid- and small-cap biotechnology companies. He rejoined Raymond James in 2025 after seven years at Piper Sandler as a key leader in building their biopharma equity research practice. Prior to Piper Sandler, he spent two years with Raymond James from 2015 to 2017, and prior to that, spent 13 years establishing and building the biopharma research effort at Robert W. Baird. He got his start in equity research at Prudential Vector Securities in 2000. Throughout his career, Chris has been recognized numerous times by the Wall Street Journal, StarMine and other entities for his equity research and earnings estimation skills. Prior to moving to equity research, he spent 10 years in the biopharmaceutical industry in various marketing and business development roles with companies such as G.D. Searle and Baxter Healthcare. He holds a BA from the Broad College of Business at Michigan State University and an MBA from the Booth School of Business at the University of Chicago. He currently serves on the board of advisors for the Financial Markets Institute and the Broad College of Business at Michigan State University.